Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT05874674
Recruiting Not applicable

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

NCT05874674 · tracked via the Priya Life Science South Korea tracker
Sponsor
Wonju Severance Christian Hospital
Phase
Not applicable
Started
2023-12-01
Last updated
2024-07-30

Condition(s) studied

Dialysis; ComplicationsBleeding

Investigational drug(s) / intervention(s)

Nafamostat Mesylate →

Nafamostat Mesylate: Comparison effect of nafamostat and cnoxan

Study summary

Comparison nafamostat and low molecular weight heparin among dialysis patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
Accepted
Inclusion Criteria: * platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month Exclusion Criteria: * cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Primary outcome measure(s)

  • Number of patients with severe bleeding — 6 month
    Brain hemorrhage (on brain CT), gastrointestinal bleeding (on EGD)

Trial sites (1)

FacilityCityRegionStatus
Yonsei Unviersity Wonju College of Medicin Wŏnju Kangwondo Recruiting

More Wonju Severance Christian Hospital trials in South Korea

CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort) Recruiting
Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS Starting soon
Flow Dynamics During Simulated Hemostasis at the Proximal and Distal Radial Arteries Starting soon
Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS Based on the Mobile Application Enrolling by invitation
Hativ® ELectrocardiogram Monitoring on Patients With Suspected Arrhythmia Recruiting

Other trials for the same condition

Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy Recruiting
Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05874674 on ClinicalTrials.gov ↗ ← All trials in South Korea